Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
NCT ID: NCT00380289
Last Updated: 2006-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
66 participants
INTERVENTIONAL
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We propose an initial open label pilot study of 10-12 patients to confirm final doses to be tested, the duration of therapy for optimum timing of the OGTT and tolerability of doses selected. The pilot study will also be used to confirm sample size calculations for the main study.The protocol for the pilot study will be identical to the main study, but there will not be a placebo phase and the treatment will not be blinded.
The main study will be double-blind, placebo controlled, cross-over study, of approximately 66 patients in which each patient receives in random order, 4 weeks treatment with either Bendrofluazide 5-10mg daily, Atenolol 50-100mg daily or combination of Bendrofluazide 2.5-5mg and Atenolol 25-50mg daily. There will be a forced titration from the lower to the higher dose stated half way through each dosing period. There will be a 1 month placebo wash-out between each dosing period.
At 0, 2 and 4 weeks of each treatment phase, patients will attend the Clinical Investigation Ward (CIW), fasting, for performance of an oral glucose tolerance test (OGTT). Blood will be drawn from an intravenous cannula, for the measurements of glucose and insulin at 0, 0.5, 1 and 2 hours.
Blood pressure will be measured at each study visit using an Omron machine. The patients will also be given a blood pressure machine to take home and will be asked to measure and record their blood pressure at least twice per week. If their blood pressure is under 110/70mmhg or over 160/110mmHg at any time or if the patient has symptoms e.g. headache or dizziness, the patient will be asked to contact study staff. If the blood pressure remains over 160/110 for two measurements, then another antihypertensive therapy may be commenced, or the patient withdrawn from the study. If blood pressure is \< 110/70 mmHg with symptoms then a decision may be made to terminate their participation in the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thiazide and beta blocker
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hypertension- either
* untreated, BP 140-170/90-110
* treated for over 1 month with drugs other than beta blockers or diuretic and BP\>140/85
* treated for over 1 month with drugs other than beta blockers or diuretic and BP\<140/85 and patient willing to change medication for eight months.
Exclusion Criteria
* Any patient who is intolerant of these medications will be excluded from the study.
* Patients with gout, asthma or any other contraindications to the study drugs will be excluded.
* Women of child bearing age not using contraception.
* Volunteers with heart failure, liver failure, renal failure, terminal illnesses (e.g. cancer)
* Volunteers not able to give informed consent
* Patients with diabetes
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cambridge University Hospitals NHS Foundation Trust
OTHER
University of Cambridge
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Professor MJ Brown, MA MSC MD FRCP
Role: PRINCIPAL_INVESTIGATOR
Addenbrookes Hosptal NHS Trust/ University of Cambridge
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Pharmacology Unit, Box 110, Level 3 ACCI, Addenbrookes Hospital
Cambridge, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mrs M Watts
Role: primary
Dr A Stears, MBBS BSc MRCP
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Stears AJ, Woods SH, Watts MM, Burton TJ, Graggaber J, Mir FA, Brown MJ. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension. 2012 May;59(5):934-42. doi: 10.1161/HYPERTENSIONAHA.111.189381. Epub 2012 Apr 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OGTT1
Identifier Type: -
Identifier Source: org_study_id